Clinical Trial Update: Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessed the effect of repaglinide on postprandial lipemia in adults with type 2 diabetes; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Prandin (repaglinide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED